US Links Famous Thyroid Medicine to Severe Health Issues

The U.S. Food and Drug Administration has escalated its probe into Vitruvias Therapeutics' 30mg thyroid tablets, elevating the recall from a lower-level alert to a Class I designation. This is the agency's most severe risk level, signifying the medication may result in grave health issues or death. The recall, initiated last month, pertains to a single batch of Thyroid Tablets, USP, identified by lot number 504950 and National Drug Code 69680-166-00.

The medication's expiration date is September 30, 2026, and it was distributed across the United States between January 31 and September 30, 2025. Out of the total 3,655 units produced, approximately 1,955 were sold.

The FDA's investigation revealed that the tablets may be superpotent, meaning they possess a potency greater than their intended strength. This superpotency can lead to an overactive thyroid, resulting in a myriad of symptoms including weight loss, heightened sensitivity to heat, fatigue, elevated blood pressure, chest pain, rapid heartbeat, and irregular heart rhythms. Pregnant women, infants, and the elderly are at the greatest risk, particularly with prolonged use of the medication.

Notably, Vitruvias Therapeutics has not reported any adverse events associated with the specific lot as of the recall announcement on August 24. The company has since ceased its operations, and its products are now in the possession or distribution of H2-Pharma LLC.